Streetbeat News

Analyst Ratings

EXPE

Benchmark analyst Daniel Kurnos maintains a Buy rating on Expedia Group (NASDAQ:EXPE) and raises the price target from $160 to $180, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:14 pm

AVGO

GOOG

GOOGL

META

MSFT

JPMorgan analyst Harlan Sur initiated coverage of Broadcom Inc (NASDAQ:AVGO) with an Overweight rating and a $1,550 price target, highlighting its leadership in AI, cloud datacenter, and semiconductor infrastructure. Broadcom's strategic partnerships with Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL), Meta Platforms Inc (NASDAQ:META), and Microsoft Corp (NASDAQ:MSFT) in custom chip (ASIC) opportunities are emphasized. Sur projects FY24 revenue and EPS close to consensus estimates and anticipates significant earnings power by the second half of 2025.

Portfolio Pulse from Anusuya Lahiri

February 06, 2024 | 7:11 pm

FDMT

REGN

4D Molecular Therapeutics (NASDAQ:FDMT) released positive Phase 2 data for 4D-150 in wet AMD, meeting investor expectations. BMO Capital Markets raised the target price to $70 from $50, maintaining an Outperform rating and naming FDMT a top pick for early 2024. The data suggests 4D-150's superiority over Regeneron's (NASDAQ:REGN) Eylea in safety and efficacy. FDMT is exploring partnerships for 4D-150's development outside the U.S., with rapid trial enrollment expected to accelerate the development timeline. FDMT shares dropped 6.6% to $30.15.

Portfolio Pulse from Vandana Singh

February 06, 2024 | 7:05 pm

NEXA

JP Morgan analyst Rodolfo Angele maintains a Neutral rating on Nexa Resources (NEXA) and raises the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:05 pm

VRTX

Vertex Pharmaceuticals (VRTX) shares dropped after the company announced its Q4 financial results and provided future guidance. Additionally, Evercore ISI downgraded VRTX from Outperform to In-Line, contributing to the negative sentiment.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:01 pm

IDXX

IDEXX Laboratories (NASDAQ:IDXX) has received mixed analyst ratings over the past three months, with a shift towards more bullish sentiment in the last 30 days. Analysts have raised their 12-month price targets, indicating an average target of $615.0, an 8.21% increase from the previous average. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, but it faces challenges with a high debt-to-equity ratio. IDXX develops and distributes diagnostic products for pets and livestock, with significant revenue from outside the U.S.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 7:00 pm

PLUG

Over the last three months, 25 financial analysts have provided diverse opinions on Plug Power (NASDAQ:PLUG), with recent ratings showing a shift towards a more cautious stance. The average 12-month price target has been adjusted to $5.14, significantly lower than the previous $8.04, indicating a downward trend in expectations. Analysts' actions, ranging from maintaining to lowering ratings and price targets, reflect changing market conditions and company performance. Plug Power's financials show a mix of positive revenue growth but challenges in net margin, ROE, and ROA, with a sound debt management position.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 7:00 pm

LCII

LCI Industries (NYSE:LCII) has received mixed analyst ratings in the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for LCII has decreased by 8.07% to $111.00. The company faces challenges in revenue growth, profitability, and asset utilization, with a notable revenue decline of -15.26% as of September 30, 2023. Despite these challenges, LCI Industries maintains a lower than average debt-to-equity ratio, indicating a healthier balance between debt and equity.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 7:00 pm

IDXX

JP Morgan analyst Chris Schott maintains an Overweight rating on IDEXX Laboratories (NASDAQ:IDXX) and raises the price target from $600 to $630.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 6:59 pm